Apogee Therapeutics, Inc. is a biotechnology company focused on developing innovative therapeutic solutions for a range of diseases by harnessing the power of immune system modulation
The company specializes in creating treatments that aim to effectively address conditions that involve dysregulated immune responses. Through its advanced research and development efforts, Apogee Therapeutics is dedicated to improving the lives of patients by providing targeted therapies that can enhance treatment outcomes and reduce the burden of chronic illnesses.
Apogee's APG990 Phase 1 data show a 60-day half-life and strong tolerability, supporting long-interval dosing. A 2025 trial will compare APG279 to Dupixent.
10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeutics, Joby Aviation, Crinetics Pharmaceuticals, Dyne Therapeutics, Summit Therapeutics, Plug Power and XPeng Inc.
As of March 14, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
U.S. stocks traded lower toward the end of trading, with the Dow Jones falling around 350 points on Tuesday. The Dow traded down 0.91% to 38,633.24 while the NASDAQ fell 1.85% to 15,906.92. The S&P 500 also fell, dropping, 1.05% to 5,076.98.
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 250 points on Tuesday. The Dow traded down 0.64% to 38,741.00 while the NASDAQ fell 1.64% to 15,942.27. The S&P 500 also fell, dropping, 0.85% to 5,087.09.
Shares of SOPHiA GENETICS SA (NASDAQSOPH) fell sharply during Tuesday’s session after the company reported worse than expected fourth-quarter earnings and issued 2024 guidance.
Apogee Therapeutics unveils promising Phase 1 data for APG777, a lead candidate for atopic dermatitis treatment. Interim results show sustained biomarker inhibition and favorable safety profile. Phase 2 trial scheduled for 2024.
U.S. stocks traded lower this morning, with the Dow Jones index falling more than 100 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.33% to 38,861.95 while the NASDAQ fell 0.82% to 16,074.48. The S&P 500 also fell, dropping, 0.42% to 5,109.27.
Sagimet and Apogee both made their trading debuts this week, raising cash for their clinical trials after upsizing their respective IPOs. Inflammation and immunology biotech Apogee had the larger of the two IPOs, as it raised $300 million.
